Suchita Waghmare

Suchita Waghmare

Auto-generated profile, based on publicly available information

Suchita Waghmare

Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, 440033, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Pharmaceutical Nanotechnology
Verified
Journal Article
Closed access
PDF file
SWSuchita Waghmare
Suchita Waghmare
RPRohini Palekar
Rohini Palekar
PSPrafulla Sabale
Prafulla Sabale
PKPramod Khedekar
Pramod Khedekar
PSPrafulla Sabale
Prafulla Sabale
VSVidya Sabale
Vidya Sabale
In order to overcome some of the drawbacks of traditional formulations, increasing emphasis has recently been paid to lipid-based drug delivery systems. Solid lipid nanoparticles (SLNs) are promising delivery methods, and they hold promise because of their simplicity in production, capacity to scale up, biocompatibility, and biodegradability of formulation components. Other benefits could be connected to a particular route of administration or the makeup of the ingredients being placed into these delivery systems. This article aims to review the significance of solid lipid nanocarriers, their benefits and drawbacks, as well as their types, compositions, methods of preparation, mechanisms of drug release, characterization, routes of administration, and applications in a variety of delivery systems with a focus on their efficacy.

11 March 2025 in Pharmaceutical Nanotechnology
Verified
Journal Article
Closed access
PDF file
RKRoshni Kunte
Roshni Kunte
PSPrafulla Sabale
Prafulla Sabale
SWSuchita Waghmare
Suchita Waghmare
MJManasi Nikam Jiwankar
Manasi Nikam Jiwankar
VSVidya Sabale
Vidya Sabale
Cancer is a leading cause of death and life-threatening disease globally. It is connected to persistent tissue damage and unregulated cellular proliferation. In females, breast cancer plays a crucial role in death rates. Chemotherapy, alongside surgery, radiation, and hormone therapy, is a first-line treatment, but its non-specific action harms both cancerous and healthy cells, causing severe side effects. The treatment options for breast cancer are based on the disease stage, which spans from stages 0 to IV. To mitigate this issue, novel strategies focusing on specific targets have been introduced in recent times. Advanced nanocarriers are focused on tumor-specific drug delivery using active targeting based on ligand-receptor identification, this approach has the potential to demonstrate enhanced efficacy compared to passive targeting strategies in the context of therapy for human breast cancer. Surface alteration can assist overcome this issue. This overview focuses on modified nano-sized carriers, including liposomes, micelles, polymeric nanocarriers, carbon dots, and gold nanoparticles. It has been studied to improve therapeutics efficacy, bioavailability, and pharmacokinetics features via mechanisms. The primary aim is no longer confined to merely enveloping cancer medications in novel formulations for diverse delivery pathways; instead, the emphasis lies on precise cancer targeting. This review focuses on the stages of breast cancer, obstacles, types of breast cancer therapies, techniques, and various nanocarriers using ligand-mediated drug delivery systems and their mechanisms.

7 July 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
SWSuchita Waghmare
Suchita Waghmare
UHUjban Hussain
Ujban Hussain
NRNilesh Rarokar
Nilesh Rarokar
PKPramod Khedekar
Pramod Khedekar
Objective: The objective of this study is to develop and validate analytical techniques for the accurate quantification, stability assessment, and quality control of curcumin-tofacitinib-loaded nanocarriers (CS-TF-NCs). Methods: A new RP-HPLC (Reverse Phase-High Performance Liquid Chromatography) and UV-spectrophotometric method was developed and validated to quantify CS (Curcumin), TF (Tofacitinib), and CS-TF-NCs (Curcumin-Tofacitinib-Nanocarriers). UV-spectrophotometry detected λmax values of 426 nm (CS) and 286 nm (TF), and shifts to 287 nm and 421 nm for nanocarrier-loaded samples, with excellent linearity (R² = 0.9994) in the range of 5–25 μg/ml. RP-HPLC analysis was found to be very sensitive with low LOD (Limit of Detection) (LOD = 0.045 μg/ml) and LOQ (Limit of Quantification) (LOQ = 0.07 μg/ml). Recovery levels were between 97% and 99%, and retention times were 2.212 and 4.285 min for CS and TF, respectively. Results: CS and TF revealed λ max values of 426 nm and 286 nm by UV-spectrophotometry, with high correlation coefficients of R² = 0.9962 and 0.998. For CS-TF-NCs, the values were determined at 287 nm and 421 nm with a high R² = 0.9994 that validates linearity for the entire range of concentration of 5–25 μg/ml. Validation through RP-HPLC has exhibited good sensitivity, LOD being 0.045 μg/ml, and high precision (%RSD<1.5%). The nanocarriers were characterized by good solubility and sustained release profiles, giving recovery and retention times of 97–99% with 2.212 and 4.285 min for CS and TF, respectively. Conclusion: This work established CS-TF-NCs as a platform with the potential to deliver targeted, effective breast cancer therapy.

24 March 2026 in Discover Chemistry
Verified
Journal Article
Open access
SWSuchita Waghmare
Suchita Waghmare
UHUjban Hussain
Ujban Hussain
RPRohini Palekar
Rohini Palekar
PBPratiksha Bramhe
Pratiksha Bramhe
NRNilesh Ramesh Rarokar
Nilesh Ramesh Rarokar
PKPramod Khedekar
Pramod Khedekar

6 March 2026 in RSC Pharmaceutics
Verified
Journal Article
Open access
PDF file
SWSuchita Waghmare
Suchita Waghmare
RPRohini Palekar
Rohini Palekar
PBPratiksha Bramhe
Pratiksha Bramhe
NRNilesh Ramesh Rarokar
Nilesh Ramesh Rarokar
PKPramod Khedekar
Pramod Khedekar
Tofacitinib, a Janus kinase (JAK) inhibitor clinically approved for rheumatoid arthritis, holds significant potential for repurposing in breast cancer therapy due to its ability to suppress the oncogenic STAT3 signaling pathway; however, its therapeutic application is hindered by poor aqueous solubility, rapid systemic clearance, and non-specific distribution. To address these limitations, this study aimed to develop hyaluronic acid (HA)-decorated Pluronic F127 (PF127) micelles to enhance the solubility, bioavailability, and targeted delivery of Tofacitinib to CD44-overexpressing breast cancer cells. A Quality by Design (QbD) approach utilizing a Box–Behnken design (BBD) was employed to systematically optimize critical process parameters—drug-to-polymer ratio, polymer concentration, and stirring temperature—to minimize particle size and polydispersity index (PDI) while maximizing entrapment efficiency. The optimized micelles exhibited a uniform particle size of 159.2 ± 3.8 nm, a narrow PDI of 0.221, a high entrapment efficiency of 91.14%, and a negative zeta potential of −24.6 mV, ensuring colloidal stability. In vitro evaluation demonstrated a sustained, diffusion-controlled drug release profile and significantly enhanced cytotoxicity against MCF-7 breast cancer cells (IC50 14.2 µg mL−1) compared to the free drug (IC50 46.8 µg mL−1), attributed to CD44-mediated cellular uptake. Furthermore, in vivo pharmacokinetic analysis in Wistar rats revealed a 4.3-fold increase in oral bioavailability and a prolonged elimination half-life compared to free Tofacitinib, while histopathological studies confirmed the formulation's biocompatibility and safety in major organs. These findings collectively support the viability of the QbD-optimized HA–PF127 micellar system as a promising nanocarrier platform for the effective oral repurposing of Tofacitinib in breast cancer treatment.

2 June 2026 in Nano-Structures & Nano-Objects
Verified
Journal Article
Closed access
SWSuchita Waghmare
Suchita Waghmare
RPRohini Palekar
Rohini Palekar
PBPratiksha Bramhe
Pratiksha Bramhe
NRNilesh Rarokar
Nilesh Rarokar
PKPramod Khedekar
Pramod Khedekar